| Synagis (palivizumab) / SOBI |
NCT01075178: Retrospective Palivizumab Study in Children With Hemodynamically Significant Congenital Heart Disease |
|
|
| Completed | N/A | 2036 | Europe | | Abbott | Severe Respiratory Syncytial Virus Infection | 01/10 | 01/10 | | |
NCT01072552: Effect of Palivizumab on Later Recurrent Wheezing in Preterm Infants |
|
|
| Completed | N/A | 444 | Japan | | Satoshi Kusuda, Scientific Committee of Recurrent Wheezing | Recurrent Wheezing, Wheezing, Asthma | 12/10 | 08/11 | | |
INSPIRA, NCT01107535: Effectiveness of Synagis (Palivizumab) Immunoprophylaxis in Preterm Infants With High Risk of Severe Respiratory Syncytial Virus (RSV) Infection |
|
|
| Completed | N/A | 82 | RoW | Synagis (palivizumab), monoclonal antibody for passive immunoprophylaxis against severe RSV disease administered according to usual clinical practice., palivizumab, Synagis | Abbott | Respiratory Syncytial Virus Infection | 02/11 | 02/11 | | |
NCT01077271: Compliance to Synagis (Palivizumab) Under Daily Pediatrician´s Conditions in Premature Infants 33 - 35 wGA |
|
|
| Completed | N/A | 124 | Europe | | Abbott, Assign Data Management and Biostatistics GmbH | Premature Infants | 05/11 | 05/11 | | |
NCT01297504: A One-Year Observation of Palivizumab in Infants at Risk for Respiratory Syncytial Virus Infection in Latin America |
|
|
| Completed | N/A | 464 | RoW | | AbbVie (prior sponsor, Abbott), Fundasamin (Argentina) | Respiratory Syncytial Virus Infection | 08/13 | 08/13 | | |
NCT01537198: Surveillance of Synagis in Korean Pediatric Patients |
|
|
| Completed | N/A | 618 | RoW | | AbbVie (prior sponsor, Abbott) | Respiratory Syncytial Virus Infection | 06/14 | 06/14 | | |
NCT02282982: Observational Program to Assess Respiratory Syncytial Virus (RSV) Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis |
|
|
| Completed | N/A | 359 | RoW | | AbbVie | Respiratory Syncytial Virus (RSV) | 05/15 | 05/15 | | |
NCT01269528: Prospective Evaluation of the Efficacy of Palivizumab Administration in Children Born at 29-32 Weeks of Gestation |
|
|
| Completed | N/A | 42 | RoW | Methacholine Challenge Test (MCT), Monthly telephone contact, Visits to the study site, Blood Test, Fractional exhaled nitric oxide | Rambam Health Care Campus | Bronchial Hyperreactivity, Infant, Premature | 08/15 | 08/15 | | |
NCT02016690: Synagis® Liquid 50mg, 100mg for Intramuscular Injection Special Investigation in Immunocompromised Children With Synagis® |
|
|
| Completed | N/A | 312 | Japan | | AbbVie | Respiratory Syncytial Virus Infection | 12/15 | 12/15 | | |
NCT01155193: Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in Germany |
|
|
| Completed | N/A | 30804 | NA | | AbbVie (prior sponsor, Abbott) | Respiratory Syncytial Virus Infections | 07/16 | 07/16 | | |
| Completed | N/A | 229 | RoW | Phone call, Text message, Control | Kosuyolu Heart Hospital, Sabanci University, Maras Necip Fazil City Hospital, Kocaeli University, Van Research and Education Hospital, Sakarya University, Sivas Numune Hospital | Congenital Heart Disease in Children, RSV | 12/20 | 06/21 | | |
Synagis, NCT06851806: Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease |
|
|
| Not yet recruiting | N/A | 138 | NA | Palivizumab 15 mg/kg | AstraZeneca | Respiratory Syncytial Virus (RSV) | 02/27 | 02/27 | | |
